RBC Capital Maintains Outperform on 89bio, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
RBC Capital's analyst Brian Abrahams has maintained an 'Outperform' rating on 89bio (NASDAQ:ETNB) but lowered the price target from $27 to $24.
November 09, 2023 | 6:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
89bio's price target has been lowered from $27 to $24 by RBC Capital, though the 'Outperform' rating is maintained.
The news is directly about 89bio and its price target being lowered by RBC Capital. This could potentially impact the stock's price in the short term as investors adjust their expectations. However, the maintained 'Outperform' rating suggests that the analyst still sees potential in the stock, which could balance out the impact of the lowered price target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100